Recent Advances in Understanding and Managing Cutaneous T-cell Lymphomas

F1000Res. 2020 May 5;9:F1000 Faculty Rev-331. doi: 10.12688/f1000research.21922.1. eCollection 2020.

Abstract

Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients' health-related quality of life. Our aims were to review the current understanding of the pathogenesis of CTCL, such as the shift in overall immune skewing with progressive disease and the challenges of making a timely diagnosis in early-stage disease because of the lack of reliable positive markers for routine diagnostics, and to discuss established and potential treatment modalities such as immunotherapy and novel targeted therapeutics.

Keywords: Cutaneous T cell lymphoma; Mycosis fungoides; Sézary Syndrome; health-related quality of life; tissue resident memory T cells.

Publication types

  • Review

Grant support

The author(s) declared that no grants were involved in supporting this work.